Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients.
The findings revealed that 40.3% of patients on Roche’s drug achieved complete remission which was sustained for at least 16 weeks without the use of steroids, compared to just 9.5% of those on mycophenolate mofetil (MMF), achieving the study’s primary endpoint.
